Low dose flurbiprofen for prevention of postendoscopic retrograde cholangiopancreatography pancreatitis

Low dose flurbiprofen for prevention of postendoscopic retrograde cholangiopancreatography pancreatitis - Low dose flurbiprofen for prevention of post endoscopic retrograde cholangiopancreatography pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011322

Enrollment

100

Registered

2013-08-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

all desease that is needed ERCP

Interventions

Patients who were scheduled to undergo ERCP were receive 50 mg of flurbiprofen infusion. The dose of flurbiprofen was reduced to 25 mg in patients weighing&lt

50 kg A medicine is not prescribed for the patient.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)older than 20years old 2)the patient performed ERCP 3) The patient who understands the details of this research and by whom the consent of research participation is got from himself/herself with a document

Exclusion criteria

Exclusion criteria: 1) acute or active pancreatitis 2)metalicstent was inserted across the papilla 3)history of endoscopic sphincterotomy 4) peptic ulcer diseases 5) aspirin-induced asthma 6) NSAIDs during the preceding 1 week 7) hypersensitivity to NSAIDs 8) pregnant or breast-feeding 9) severe renal dysfunction, 10) the patient whom the doctor in attendance judged to be unsuitable

Design outcomes

Primary

Measure	Time frame
Does pancreatitis happened post ERCP or not	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026